Company Overview and News


Add NMUS
to your dashboard

Headline News

Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee

2017-11-09 marketwired
COSTA MESA, CA--(Marketwired - Nov 9, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced that it has submitted a demand commencing arbitration against Schneider Finance, LLC and SB Securities, Ltd., both affiliates of Schneider Brothers Ltd., as well as other individuals. SB Securities, Ltd. also uses the name "Schneider Securities." In the petition, the Company asserts, among other things, breach of contract against Schneider Finance, LLC for its failure to close its purchase of 1,000,000 shares of Series E Preferred Stock of the Company for gross proceeds of $20,000,000 as required by the securities purchase agreement signed May 3, 2017. (17-0)

NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings

2017-11-06 marketwired
COSTA MESA, CA--(Marketwired - Nov 6, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data obtained from the company's research and development partner, the University of Mississippi (UM), will be presented at upcoming scientific meetings in November. (17-0)

Politics Is The Main Uncertainty For GW Pharma

2017-11-02 seekingalpha
The future of the somewhat obscure Rohrbacher-Farr Amendment could have the ultimate say on marijuana stocks. (104-1)

Nemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing

2017-11-01 marketwired
COSTA MESA, CA--(Marketwired - Nov 1, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that it closed a Securities Purchase Agreement with certain purchasers for the sale of 2,000 shares of Series F Preferred Stock for gross proceeds of $2,000,000. Each share of preferred stock is convertible into shares of common stock at a conversion price of $0.15 per share. Nemus has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares of common stock underlying the Preferred Stock. (17-1)

BRIEF-Nemus Bioscience provides update on previously announced $20 mln Schneider financing

2017-10-13 reuters
* Nemus Bioscience provides further update on previously announced $20 million Schneider financing Source text for Eikon: Further company coverage: (2-0)

NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing

2017-10-13 marketwired
COSTA MESA, CA--(Marketwired - Oct 13, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced a further update to its news releases dated May 4, 2017 and July 11, 2017 with respect to the signing of a private placement with Schneider Finance LLC, an affiliate of Schneider Brothers Ltd, a global closed investment fund, for the sale of 1,000,000 shares of Series E Preferred Stock of the Company for gross proceeds of $20,000,000. (17-0)

NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting

2017-08-07 marketwired
COSTA MESA, CA--(Marketwired - Aug 7, 2017) -   NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data recently obtained from the company's research and development partner, the University of Mississippi (UM), will be presented at the American Association of Pharmaceutical Scientists (AAPS) meeting to be held in San Diego, CA on November 12-15, 2017. The data will be presented by Dr. Soumyajit Majumdar, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy at the University and lead scientist of the Nemus ophthalmic platform discovery initiative.

Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

2017-08-02 marketwired
COSTA MESA, CA--(Marketwired - Aug 2, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data recently obtained from the company's research and development partner, the University of Mississippi (UM), will be presented on August 12th at the Chemistry and Pharmacology of Drug Abuse Conference supported by the National Institute of Drug Abuse (NIDA) meeting held at Northeastern University in Boston, MA.

NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting

2017-07-17 marketwired
COSTA MESA, CA--(Marketwired - Jul 17, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data recently obtained from the company's research and development partner, the University of Mississippi (UM), was accepted for presentation at the 2017 Annual Meeting of the Society of Neuroscience held in Washington, D.C. on November 11th-15th. The data being presented will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.

Up In Smoke: Why Recreational Marijuana's Days Are Numbered

2017-07-11 seekingalpha
Although some states have amended their own laws to loosen restrictions on the recreational use of marijuana, it is still illegal under federal law.

NEMUS Bioscience Provides Update on Previously Announced $20 Million Schneider Financing

2017-07-11 marketwired
COSTA MESA, CA--(Marketwired - Jul 11, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced an update to its news release dated May 4, 2017 with respect to the signing of a private placement with Schneider Finance LLC, an affiliate of Schneider Brothers Ltd, a global closed investment fund with over USD $500 million in assets, for the sale of 1,000,000 shares of Series E Preferred Stock of the Company for gross proceeds of $20,000,000.

High hopes ride on marijuana painkillers amid opioid crisis

2017-06-23 reuters
A handful of drugmakers are taking their first steps toward developing marijuana-based painkillers, alternatives to opioids that have led to widespread abuse and caused the U.S. health regulator to ask for a withdrawal of a popular drug this month.

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review 2017 - Dominant Molecular Targets Vary Across Each of the Four Pipelines - Research and Markets

2017-05-29 prnewswire
Research and Markets has announced the addition of the "Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017" report to their offering.

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong

2017-05-17 marketwired
COSTA MESA, CA--(Marketwired - May 17, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that patents have been granted in Canada and Hong Kong covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), as well as other amide-ester forms of cannabinoid-based molecules. These patents are licensed to Nemus by the University of Mississippi, and further broaden the potential commercial territories for THCVHS.

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

2017-05-09 marketwired
COSTA MESA, CA--(Marketwired - May 9, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that an additional United States patent has been granted covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), as well as other amide-ester forms of cannabinoid-based molecules, for use in the treatment of glaucoma. This second patent, which is also licensed to Nemus by the University of Mississippi, further expands the intellectual property (IP) estate into methods of delivery of THCVHS into the eye, by formulating the prodrug into a nanoparticle composition.

CUSIP: 64046J100